Cat. No.: HY-100972

ARV-771

29 Cited Publications

Customer Review

Based on 29 publication(s) in Google Scholar

ARV-771 is a potent BET PROTAC based on E3 ligase von Hippel-Lindau with K_ds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively.
(Pink: BET ligand (HY-78695); Blue: VHL ligand (HY-112078); Black: linker).

For research use only. We do not sell to patients.

Purity: 99.82%
CAS No.: 1949837-12-0
Formula: C₄₉H₆₀ClN₉O₇S₂
Molecular Weight:986.64

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

ARV-771 Chemical Structure

CAS No.: 1949837-12-0

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

ARV-771 is a potent BET PROTAC based on E3 ligase von Hippel-Lindau with K_ds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively^[1]. (Pink: BET ligand (HY-78695); Blue: VHL ligand (HY-112078); Black: linker).

IC₅₀ & Target^[1]

BRD2(1)

34 nM (Kd)

BRD2(2)

4.7 nM (Kd)

BRD3(1)

8.3 nM (Kd)

BRD3(2)

7.6 nM (Kd)

BRD4(1)

9.6 nM (Kd)

BRD4(2)

7.6 nM (Kd)

All PROTACs Isoforms :

All Epigenetic Reader Domain Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.64 μM Compound: ARV-771	Antiproliferative activity against human normal (non-senescent) A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human normal (non-senescent) A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38635879]
A549	IC₅₀	603 nM Compound: ARV-771	Antiproliferative activity against human senescent A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human senescent A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38635879]
CWR22R	EC₅₀	44 nM Compound: 22; ARV-771	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by Celltiter-Glo cell viability assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by Celltiter-Glo cell viability assay	[PMID: 34881891]
EOL1	IC₅₀	1.5 nM Compound: ARV-771; 34	Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth	[PMID: 36202064]
HeLa	IC₅₀	183 nM Compound: 35; ARV-771	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 35763424]
HeLa	IC₅₀	183 nM Compound: ARV-771	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38160619]
HFF-1	IC₅₀	1.1 μM Compound: ARV-771	Antiproliferative activity against human HFF-1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HFF-1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38160619]
HK-2	IC₅₀	0.16 μM Compound: ARV-771	Antiproliferative activity against human HK-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HK-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38160619]
HL-60	IC₅₀	1.5 nM Compound: ARV-771; 34	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth	[PMID: 36202064]
MCF7	IC₅₀	120.4 nM Compound: ARV-771	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 38160619]
MOLM-13	IC₅₀	7.45 nM Compound: ARV-771	Growth inhibition of human MOLM13 cells after 96 hrs by CCK8 assay Growth inhibition of human MOLM13 cells after 96 hrs by CCK8 assay	[PMID: 30019901]
MV4-11	IC₅₀	0.43 nM Compound: ARV-771	Growth inhibition of human MV4-11 cells after 96 hrs by CCK8 assay Growth inhibition of human MV4-11 cells after 96 hrs by CCK8 assay	[PMID: 30019901]
NIH3T3	IC₅₀	0.21 μM Compound: ARV-771	Antiproliferative activity against mouse 3T3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse 3T3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38160619]
OVCAR-8	IC₅₀	215 nM Compound: ARV-771	Antiproliferative activity against human OVCAR-8 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human OVCAR-8 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38160619]
RS4-11	IC₅₀	2.4 nM Compound: ARV-771	Growth inhibition of human RS4:11 cells after 96 hrs by CCK8 assay Growth inhibition of human RS4:11 cells after 96 hrs by CCK8 assay	[PMID: 30019901]
T47D	IC₅₀	13 nM Compound: ARV-771	Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38160619]
VCaP	DC₅₀	<5 nM Compound: 101; ARV-771	Degradation of BRD4 in human VCaP cells after 16 hrs by Western blot analysis Degradation of BRD4 in human VCaP cells after 16 hrs by Western blot analysis	[PMID: 30542529]
VCaP	DC₅₀	<5 nM Compound: 47; ARV-771	Protac activity against VHL/BRD3 in human VCaP cells assessed as induction of BRD3 protein degradation by reverse phase protein array analysis Protac activity against VHL/BRD3 in human VCaP cells assessed as induction of BRD3 protein degradation by reverse phase protein array analysis	[PMID: 31035238]
Z-138	IC₅₀	142 nM Compound: 101; ARV-771	Induction of apoptosis in human ibrutinib-resistant Z138 cells after 48 hrs by Annexin-V/propidium iodide staining based assay Induction of apoptosis in human ibrutinib-resistant Z138 cells after 48 hrs by Annexin-V/propidium iodide staining based assay	[PMID: 30542529]

In Vitro

ARV-771, a small-molecule pan-BET PROTAC degrader, demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition. ARV-771 potently degrades BRD2/3/4 in 22Rv1 cells with a DC₅₀ less than 5 nM. c-MYC protein is a downstream effector of BET proteins. Treatment with ARV-771 results in depletion of c-MYC with an IC₅₀ of less than 1 nM. ARV-771 shows strong antiproliferative effect on 22Rv1, VCaP, and LnCaP95 cell lines. ARV-771 treatment has a pronounced effect on cell morphology consistent with apoptosis. FL-AR and AR-V7 mRNA are down-regulated upon treatment with 10 nM ARV-771 in VCaP cells. ARV-771 has an antiandrogenic effect on a number of AR-regulated genes in VCaP cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Treatment of non castrated male Nu/Nu mice bearing AR-V7+ 22Rv1 tumor xenografts with daily subcutaneous injections of ARV-771 at 10 mg/kg for 3 d results in 37% and 76% down-regulation of BRD4 and c-MYC levels, respectively, in tumor tissue. A marked down-regulation in levels of AR-V7 is observed in the 22Rv1 tumors after ARV-771 treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1949837-12-0
Appearance Solid
Molecular Weight 986.64
Formula C₄₉H₆₀ClN₉O₇S₂
Color White to light yellow
SMILES

CC1=C(C)SC2=C1C(C3=CC=C(C=C3)Cl)=N[C@H](C4=NN=C(N42)C)CC(NCCOCCCOCC(N[C@H](C(N5C[C@@H](C[C@H]5C(N[C@@H](C)C6=CC=C(C=C6)C7=C(C)N=CS7)=O)O)=O)C(C)(C)C)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (29)

All WBOthers

Sort by:

Journal Impact Factor

Cell

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. [Abstract]

2024 Jan 4;187(1):166-183.e25. PMID: 38181739
Mol Cell

Cullin-RING ligases employ geometrically optimized catalytic partners for substrate targeting. [Abstract]

2024 Apr 4;84(7):1304-1320.e16. PMID: 38382526

ARV-771 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1304-1320.e16. [Abstract]

ARV-771 (500 nM; 6 h). Representative western blots comparing protein levels upon treatment with PROTACs in control or UBE2R1/UBE2R2 DKO HEK293T cells. Notice that ectopic expression of either UBE2R1 (lanes 9-12) or UBE2R2 (lanes 13-16) completely restored BRD4 degradation with ARV-771.
Mol Cell

TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains. [Abstract]

2021 Apr 1;81(7):1411-1424.e7. PMID: 33567268
Mol Cell

Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation. [Abstract]

2019 Aug 22;75(4):849-858.e8. PMID: 31442425
Nat Commun

Intrinsic signaling pathways modulate targeted protein degradation. [Abstract]

2024 Jul 2;15(1):5379. PMID: 38956052
Nat Chem Biol

Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders. [Abstract]

2023 Mar;19(3):323-333. PMID: 36329119

ARV-771 purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2023 Mar;19(3):323-333. [Abstract]

Heatmap depicting mean log2 fold-enrichment of VHL mutations normalized to maximum log2 fold-changes vs. DMSO across ARV-771 (500 nM; 7 days) treated for 7 days. n = 2 independent measurements.
Nat Chem Biol

Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. [Abstract]

2021 Nov;17(11):1157-1167. PMID: 34675414
Nat Chem Biol

Rational discovery of molecular glue degraders via scalable chemical profiling. [Abstract]

2020 Nov;16(11):1199-1207. PMID: 32747809
J Adv Res

Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma. [Abstract]

2025 Jul 4:S2090-1232(25)00504-1. PMID: 40617410
J Control Release

Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles. [Abstract]

2021 Feb 10;330:1244-1249. PMID: 33234362
Clin Cancer Res

Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors. [Abstract]

2019 Jun 1;25(11):3404-3416. PMID: 30796033
Nat Struct Mol Biol

CAND1 inhibits Cullin-2-RING ubiquitin ligases for enhanced substrate specificity. [Abstract]

2024 Feb;31(2):323-335. PMID: 38177676
Cell Rep

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. [Abstract]

2021 Jan 5;34(1):108532. PMID: 33406420
J Med Chem

Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. [Abstract]

2020 Jul 9;63(13):7186-7210. PMID: 32453591
JCI Insight

Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. [Abstract]

2022 May 23;7(10):e151353. PMID: 35439169
Biochem Pharmacol

Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. [Abstract]

2025 Jul 12:241:117159. PMID: 40659131
Philos Trans R Soc Lond B Biol Sci

Development of compounds for targeted degradation of mammalian cryptochrome proteins. [Abstract]

2025 Jan 23;380(1918):20230342. PMID: 39842482
Bioorg Chem

A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. [Abstract]

2022 Feb:119:105505. PMID: 34838332
Structure

PROTAC-mediated activation, rather than degradation, of a nuclear receptor reveals complex ligand-receptor interaction network. [Abstract]

2024 Dec 5;32(12):2352-2363.e8. PMID: 39389062
Drug Metab Dispos

Applications of contemporary tools to measure plasma protein binding of targeted protein degraders. [Abstract]

2025 May;53(5):100066. PMID: 40286535
ACS Chem Biol

Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. [Abstract]

2019 Oct 18;14(10):2215-2223. PMID: 31553577
Curr Issues Mol Biol

Role of the Super-Enhancer Component Bromodomain Protein 4 in the Radiation Response of Human Head and Neck Squamous Cell Carcinoma Cells. [Abstract]

2026 Jan 10;48(1):71. PMID: 41614901
bioRxiv

2025 April 16.
bioRxiv

2023 Apr 21.
Patent

US20230124700A1.
Patent

US20220288051A1.
Methods Mol Biol

Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells. [Abstract]

2021:2365:151-171. PMID: 34432243
Research Square Preprint

2020 Dec.
Martin-Luther-Universität Halle-Wittenberg

2020 Dec.

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (50.68 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0135 mL

5.0677 mL

10.1354 mL

5 mM

0.2027 mL

1.0135 mL

2.0271 mL

10 mM

0.1014 mL

0.5068 mL

1.0135 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

ARV-771 is dissolved in DMSO. 22Rv1 cells (5,000 cells per well) are dosed with ARV-771 serially diluted 1:3 for a 10-point dose curve for 72 h. CellTiter-Glo Luminescent Cell Viability Assay is added, and the plate is read on a luminometer. Data are analyzed and plotted using GraphPad Prism software^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: Mice bearing tumors are treated with ARV-771 (5, 10, 30, 50 mg/kg) for up to 3 wk, depending on the experiment. Mice are sacrificed 8 h after the final dose. Plasma and tissues are harvested and flash frozen for further analysis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.0135 mL	5.0677 mL	10.1354 mL	25.3385 mL
	5 mM	0.2027 mL	1.0135 mL	2.0271 mL	5.0677 mL
	10 mM	0.1014 mL	0.5068 mL	1.0135 mL	2.5339 mL
	15 mM	0.0676 mL	0.3378 mL	0.6757 mL	1.6892 mL
	20 mM	0.0507 mL	0.2534 mL	0.5068 mL	1.2669 mL
	25 mM	0.0405 mL	0.2027 mL	0.4054 mL	1.0135 mL
	30 mM	0.0338 mL	0.1689 mL	0.3378 mL	0.8446 mL
	40 mM	0.0253 mL	0.1267 mL	0.2534 mL	0.6335 mL
	50 mM	0.0203 mL	0.1014 mL	0.2027 mL	0.5068 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

ARV-771

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

PROTAC Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ARV-771

All PROTACs Isoforms

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Publications (29)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

ARV-771

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

PROTAC Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ARV-771

All PROTACs Isoforms

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Publications (29)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

ARV-771 Related Classifications

Cat. No.: HY-100972